Neuroleptic malignant syndrome (NMS) is a rare but serious side effect of antipsychotic medications that are often prescribed to treat a wide variety of mental disorders. This syndrome, which is also sometimes called neuroleptic syndrome or malignant syndrome, affects the body's nervous system and can have severely debilitating neurological, physical, and psychological consequences. While the exact cause is not completely understood, NMS is often brought on by the sudden or excessive use of antipsychotic medications. Those who are at highest risk for developing NMS are individuals who have recently changed their dosage of antipsychotic drugs, those with pre-existing medical or neurological conditions, the elderly, and people with a family history of NMS. The most common symptoms of this disorder include muscular rigidity, elevated fever, autonomic dysfunction, tremor, and altered mental status. It is important to note that not all of these symptoms have to be present in order for a diagnosis to be made. Treatment for NMS includes stopping the antipsychotic medication that triggered the syndrome, treating symptoms with antipyretic agents and benzodiazepines, and providing supportive care, such as fluids, nutrition, and ventilation if necessary. In some cases, patients may require the use of other medications to reduce their muscle rigidity and manage their psychological symptoms. It is important to recognize the signs of NMS, as it can be life-threatening if left untreated. Anyone taking an antipsychotic medication should be aware of the risk associated with this disorder and seek medical attention immediately if any of the NMS symptoms arise. Early diagnosis and prompt treatment are the key to a complete recovery.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States